**CDD Grant Funding Application**

Not to exceed three (3) pages in total (including budget)

|  |  |  |  |
| --- | --- | --- | --- |
| 1. **Principal investigator(s)**
 |  | **PI Title / Department:** |  |
| 1. **Project Type**
 | \_\_\_ Small molecule\_\_\_ Biologic | \_\_\_ High-Throughput Screening \_\_\_ Med Chem/SAR \_\_\_ In Vivo Proof of Concept \_\_\_ ADME/Pharmacokinetics \_\_\_ Other. Please Specify \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_  |
| 1. **Project Title**
 |  |
| 1. **Therapeutic**

**hypothesis** | What coherent and supportable hypothesis is expected to convey therapeutic benefit?What data link the pathway/target to human disease? |  |
| 1. **Target defined**
 | What is the drug target and understanding of the type of intervention desired?  |  |
| 1. **Project status & enabling expertise**
 | What is the current project status. What know-how, experience and/or expertise do you have that is not readily available to others? |  |
| 1. **Competitor(s) or Partners**
 | What is the current standard and what is being developed? What is your unfair advantage? What downstream partners might have interest in your work? |  |
| 1. **Proposed Investigation & Milestone(s)**
 | What work will be done? What are key points that serve as go/no go points along the way? |  |

1. **Budget & Milestones** (Example shown below)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Tranche # / Pre-Requisite** | **Specific activity** | **Funds required** | **Milestone** **Deliverable & Success Criterion** | **Delivery by** |
| **Tranche 1 / no pre-requisite** | Single Drug Dose Response in ABC model with Drug 1, Drug 2, Drug 3, Drug 4 | $25,000 | At least two drugs which show 15% reduction in liver ABC accumulation at non-toxic doses | 6 mo from NoA |
| **Tranche 2 / pre-requisite:** success in Tranche 1 and Quotes from CRO for PK | Drug pair testing of ideal concentrations in ABC model to assess synergy (Drug 1 and Drug 2, Drug 1 and Drug 2, Drug 3 and Drug 4) | $20,000 | At least one drug combination with a combination index of <1.0 via isobologram analysis and lack of toxicity | 10 mo from NoA |
| **Tranche 3 / pre-requisite:** success in Tranche 2 | Regulatory Analysis & Commercialization strategy for re-purposing pathway | $5,000 | Identification of a viable regulatory & commercial strategy leveraging IP to navigate clinical trials | 12 mo from NoA |
| ***Total (up to $50,000)*** | $50,000 |  |